04/23/2026
In 2023 the FDA restricted peptides from licensed compounding pharmacies.
BioFuse lost access like every other clinic.
The difference is what we did next.
A lot of providers found workarounds — gray market websites, research-only labels, overseas suppliers with no quality testing and no physician involved. They kept selling and called it good enough.
We did not. We went without until we found legitimate 503A licensed pharmacy partners with real prescriptions and pharmaceutical-grade sourcing. It took time. It cost us. We did it anyway.
Today the FDA formally began removing BPC-157, KPV, MOTS-c, Epitalon, and 8 other peptides from the restricted list — the first real step toward regulated access for the entire industry.
For us it is not a turning point. It is validation.
If you have been wanting peptide therapy done the right way — link in bio.
